Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16INK4a status
- HEADLAcE Study Group,
- Laura Sichero(Author),
- Marta Tagliabue(Author),
- Giana Mota(Author),
- Silvaneide Ferreira(Author),
- Rafaella A.L. Nunes(Author)
- University of São Paulo,
- Istituto di Ricovero e Cura a Carattere Scientifico and International Breast Cancer Study Group,
- ,
- Universidad Científica del Sur,
- Instituto Nacional de Enfermedades Infecciosas,
- International Agency for Research on Cancer
Research Output:
Contribution to journal
Article
Peer-reviewPublication Information
Output type
Research Output:
Contribution to journal
Article
Peer-reviewOriginal language
EnglishPages from-to (Number of pages)
Pages 122-133 (12 pages)Journal (Volume, Issue Number)
Head & neck (Volume 44, Issue 1)Publication milestones
- Accepted/In press - 2021
- Published - 01/2022
Publication status
Published - 01/2022
ISSN
1043-3074Publication IDs
- Scopus: 85122839302
- PubMed: 34726297
Abstract
Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16INK4a in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. Methods: HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16INK4a immunohistochemistry. Results: HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16INK4a positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Conclusions: Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.
Funding Details
The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer /World Health Organization. This work was supported by the São Paulo Research Foundation (FAPESP) (Grant No. 2017/04020‐7 to LLV); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant No. 306326/2015‐9 to LLV and 303431/2018‐0 to LS); Merck Sharp and Dohme (Investigator Initiated Studies IISP # 56004 to LLV); Fondo Nacional de Desarollo Científico, Tecnológico y de Innovación Tecnológica (Fondecyt) (096‐2017‐FONDECYT to CAC); Italian Ministry of Health (with Ricerca Corrente and 5x1000 funds to SC, Marta Tagliabue); Instituto de Salud Carlos III (ISCIII) through AESI 2017 (Grant No. AC17CIII/00003 to MP) and within the EU‐LAC Health framework. The authors are particularly grateful to Laura Leguina (Pathology Service, Hospital de Oncologia Maria Curie), Victoria Cachau, Maria Alejandra Avagnina, Andrea Paes de Lima (Pathology Department, Hospital de Clinicas General San Martín) and María Luisa Paparella (Faculty of Odontology, Universidad de Buenos Aires), Buenos Aires, Argentina for their support and commitment in sample recruitment. We also acknowledge the collaboration of Prof. Evandro Sobroza de Mello and Allane dos Santos Ferreira from the Department of Pathology of Faculdade de Medicina, Universidade de São Paulo, at ICESP.
The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer /World Health Organization. This work was supported by the São Paulo Research Foundation (FAPESP) (Grant No. 2017/04020-7 to LLV); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant No. 306326/2015-9 to LLV and 303431/2018-0 to LS); Merck Sharp and Dohme (Investigator Initiated Studies IISP # 56004 to LLV); Fondo Nacional de Desarollo Científico, Tecnológico y de Innovación Tecnológica (Fondecyt) (096-2017-FONDECYT to CAC); Italian Ministry of Health (with Ricerca Corrente and 5x1000 funds to SC, Marta Tagliabue); Instituto de Salud Carlos III (ISCIII) through AESI 2017 (Grant No. AC17CIII/00003 to MP) and within the EU-LAC Health framework. The authors are particularly grateful to Laura Leguina (Pathology Service, Hospital de Oncologia Maria Curie), Victoria Cachau, Maria Alejandra Avagnina, Andrea Paes de Lima (Pathology Department, Hospital de Clinicas General San Martín) and María Luisa Paparella (Faculty of Odontology, Universidad de Buenos Aires), Buenos Aires, Argentina for their support and commitment in sample recruitment. We also acknowledge the collaboration of Prof. Evandro Sobroza de Mello and Allane dos Santos Ferreira from the Department of Pathology of Faculdade de Medicina, Universidade de São Paulo, at ICESP.
Conselho Nacional de Desenvolvimento Científico e Tecnológico, Grant/Award Numbers: 303431/2018‐0, 306326/2015‐9; Fondo Nacional de Desarrollo Científico y Tecnológico, Grant/Award Number: 096‐2017; Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant/Award Number: 2017/04020‐7; Instituto de Salud Carlos III, Grant/Award Number: AC17CIII/00003; Italian Ministry of Health; Merck Sharp and Dohme, Grant/Award Number: IISP#56004 Funding information
FundersFunding numbers
AESI
-EU-LAC
-Hospital de Clinicas General San Martín
-Hospital de Oncologia Maria Curie
-ICESP
-IISP
-International Agency for Research on Cancer/World Health Organization
-WHO
-MSD
56004
FAPESP
2017/04020‐7
FONDECYT
096‐2017, 096‐2017‐FONDECYT
Ministero della Salute
5x1000
CNPq
306326/2015‐9, 303431/2018‐0
ISCIII
AC17CIII/00003
UBA
-USP
-FONDECYT
-Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Citations
6
Captures
28
Sustainable Development Goals
SDG 3 Good Health and Well